Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) 2 year CAGR for the Trailing 12 Months (TTM) ending January 31, 2024: 94.16%

Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) 2 year CAGR is 94.16% for the Trailing 12 Months (TTM) ending January 31, 2024, a 1,347.46% change year over year. Return on net assets measures the profitability of a company relative to its net assets, which include total non-current assets and working capital. It is calculated by dividing the net income by the sum of total non-current assets and working capital. This ratio indicates the return generated for each unit of net asset investment made by the company. A higher return on net assets suggests better profitability and efficient utilization of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending January 31, 2023 was -5.67%, a -46.42% change year over year.
Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending January 31, 2022 was -3.87%, a 41.62% change year over year.
Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending January 31, 2021 was -6.63%, a -77.79% change year over year.
Kalvista Pharmaceuticals Inc Return on Net Assets (RONA) for the Trailing 12 Months (TTM) ending January 31, 2020 was -3.73%, a -59.67% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends